Receptor tyrosine-protein kinase erbB-2

From Ganfyd

Jump to: navigation, search
Common Name:Receptor tyrosine-protein kinase erbB-2
Other Names, such as IUPAC Name
human epidermal growth factor receptor 2 protein, metastatic lymph node gene 19 protein, tyrosine kinase-type cell surface receptor HER, MLN 19, proto-oncogene Neu, proto-oncogene c-ErbB-2, p185erbB2, CD340
Biochemical Information
Molecular Structure
Important Issues in Man
Relevant Clinical Literature
UK Guidance
Other Wikis
Wikipedia on Receptor tyrosine-protein kinase erbB-2 (Less technical, ? quality control)

Indicates aggression in breast cancer; specific treatment

The HER2 protein, also known amongst other names as, ErbB2 or neu, and coded for by the ERBB2 gene at 17q12 derives its name from human epidermal growth factor receptor 2, indicating its similarity to epidermal growth factor receptor (EGFR). HER2 interacts with other members of the EGFR family and functions as a co-receptor for epidermal growth factor or equivalent ligands.

Activation of the co-receptor complex transduces a signal, which in turn, stimulates tyrosine kinase activity in the intracellular domain. In normal cells, HER2 is a proto-oncogene, conveying the signal downstream where it stimulates cell growth and differentiation.

Abnormal expression of HER2 protein is thought to result in excess growth stimulation, converting HER2 into an oncogene. About 20-25% of breast cancers are strongly HER2 positive and are associated with a more aggressive phenotype. 10-15% of gastric adenoacarcinoma as positive.

The two commonly used methods of testing for HER2 are immunohistochemistry and FISH.

HER2 can be blocked using a synthetic humanised monoclonal antibody called trastuzumab, although the mechanisms of action may be more complex than just receptor antagonism. Pertuzumab is also a monoclonal antibody that interferes with Her2 dimerisation. There is on-going research into using both agents synergistically.

Histological Assessment of Her2 in Breast Cancer

Both immunohistochemistry and FISH can be used. The results of either method are either positive, negative or equivocal. A single method will suffice if the result is positive or negative, but equivocal results should be corroborated with the other method.[1]

Her2 immunostaining. Faint membrane staining in >10% of tumour, but only part of membrane. This would be a score of 1/3.
Her2 immunostaining. There is complete membrane staining in >30% of tumour, but only moderately strong staining. This would be a score of 2/3.
Her2 immunostaining. This would be a score of 3/3.

Her2 immunohistochemistry is graded as follows:

No staining or <10% membrane staining in tumour cells
Faint membrane staining is detected in >10% of tumour cells, but cells are only stained in part of the membrane
Weak to moderate staining of the entire membrane in >30% of tumour cells
Uniform intense staining of the entire membrane in >30% of tumour cells.

Histological Assessment of Her2 in Gastric Cancer

~20% of gastric adenocarcinomas are positive, increasing in proportion to about a third in gastro-oesophageal junction tumours and intestinal-type tumours. Unlike breast cancer, there is more heterogeneity within the tumours. Following preliminary assessment[2], the recommended scoring system differs from breast cancer:[3] completely circumferential staining is not required, i.e. basolateral staining will suffice, background dysplasia can be counted (whereas breast DCIS is not) and only a small group of cells is sufficient for positive staining. Intensity also follows the breast scoring system with the rule of thumb that score 3 staining is visible at ~5x, score 2 visible at 10-20x and 1+ visible requiring 40x magnification. Immunohistochemistry is the first-line modality with recourse to FISH only in scores of 2. One issue is that different antibody clones result in differing levels of staining.